MedPath

LEO LABORATORIES LIMITED

🇮🇪Ireland
Ownership
-
Employees
-
Market Cap
-
Website

A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis

Phase 1
Completed
Conditions
Psoriasis Vulgaris
Interventions
Drug: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
First Posted Date
2010-04-16
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
24
Registration Number
NCT01105286
Locations
🇫🇷

LEO Pharma investigational site, Nice, France

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Phase 2
Completed
Conditions
Scalp Psoriasis
Interventions
Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
First Posted Date
2010-03-10
Last Posted Date
2025-03-11
Lead Sponsor
LEO Pharma
Target Recruit Count
31
Registration Number
NCT01083758
Locations
🇺🇸

Rady Children's Hospital San Diego, San Diego, California, United States

🇺🇸

Leavitt Medical Associates of Florida, Inc., Ormond Beach, Florida, United States

🇺🇸

Peachtree Dermatology Associates, PC, Atlanta, Georgia, United States

and more 2 locations

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Completed
Conditions
Scalp Psoriasis
First Posted Date
2010-01-20
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
724
Registration Number
NCT01052467
Locations
🇩🇪

University Clinical Schleswig-Holstein, Campus Kiel, Kiel, Germany

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

Phase 1
Completed
Conditions
Psoriasis Vulgaris
Interventions
Drug: Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle
First Posted Date
2010-01-06
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
24
Registration Number
NCT01043224
Locations
🇫🇷

LEO Pharma investigational site, Nice, France

LEO 29102 Cream in the Treatment of Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2009-12-23
Last Posted Date
2025-03-10
Lead Sponsor
LEO Pharma
Target Recruit Count
183
Registration Number
NCT01037881
Locations
🇨🇦

Windsor Clinical Research Inc., Windsor, Ontario, Canada

🇫🇮

Helsinki University Central Hospital, Helsinki, Finland

🇩🇪

Klinik und Poliklinik für Dermatologie, Universität Bonn, Bonn, Germany

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Phase 2
Completed
Conditions
Papulopustular Rosacea
Interventions
Drug: Azelaic acid foam 15%
Drug: Vehicle foam
First Posted Date
2009-12-03
Last Posted Date
2020-03-31
Lead Sponsor
LEO Pharma
Target Recruit Count
401
Registration Number
NCT01025635

A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas

Phase 3
Completed
Conditions
Psoriasis Vulgaris
Interventions
First Posted Date
2009-11-04
Last Posted Date
2025-03-07
Lead Sponsor
LEO Pharma
Target Recruit Count
40
Registration Number
NCT01007591
Locations
🇫🇷

CHU Saint-Etienne Hôpital NOrd, Saint-Etienne, France

LEO 27847 - A Study in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2009-11-04
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
48
Registration Number
NCT01007383
Locations
🇬🇧

Covance Clinical Research Unit Ltd., Leeds, United Kingdom

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Phase 1
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: LEO 29102 cream
Drug: LEO 29102 placebo cream
First Posted Date
2009-11-01
Last Posted Date
2025-02-24
Lead Sponsor
LEO Pharma
Target Recruit Count
36
Registration Number
NCT01005823
Locations
🇳🇱

PRA International, University Medical Centre, Groningen, Netherlands

Fucidin® Cream in the Treatment of Impetigo

Phase 4
Terminated
Conditions
Impetigo
Interventions
First Posted Date
2009-09-30
Last Posted Date
2025-03-06
Lead Sponsor
LEO Pharma
Target Recruit Count
58
Registration Number
NCT00986856
Locations
🇸🇪

Vårdcentrum Kungshöjd, Göteborg, Sweden

🇳🇴

Institute of Internal Medicin, Haukeland University Hospital, Bergen, Norway

© Copyright 2025. All Rights Reserved by MedPath